EGAGenomicsIllumina HiSeq 2500Otherhttps://ega-archive.org/studies/EGAS00001001702EGAEGA study EGAS00001001702RNA sequence of HUB_5 cell cultureEGArestricted<h4>Background</h4>Technology development to enable the culture of human prostate cancer (PCa) progenitor cells is required for the identification of new, potentially curative therapies for PCa.<h4>Objective</h4>We established and characterized patient-derived conditionally reprogrammed cells (CRCs) to assess their biological properties and to apply these to test the efficacies of drugs.<h4>Design, setting, and participants</h4>CRCs were established from seven patient samples with disease ranging from primary PCa to advanced castration-resistant PCa (CRPC). The CRCs were characterized by genomic, transcriptomic, protein expression, and drug profiling.<h4>Outcome measurements and statistical analysis</h4>The phenotypic quantification of the CRCs was done based on immunostaining followed by image analysis with Advanced Cell Classifier using Random Forest supervised machine learning. Copy number aberrations (CNAs) were called from whole-exome sequencing and transcriptomics using in-house pipelines. Dose-response measurements were used to generate multiparameter drug sensitivity scores using R-statistical language.<h4>Results and limitations</h4>We generated six benign CRC cultures which all had an androgen receptor-negative, basal/transit-amplifying phenotype with few CNAs. In three-dimensional cell culture, these cells could re-express the androgen receptor. The CRCs from a CRPC patient (HUB.5) displayed multiple CNAs, many of which were shared with the parental tumor. We carried out high-throughput drug-response studies with 306 emerging and clinical cancer drugs. Using the benign CRCs as controls, we identified the Bcl-2 family inhibitor navitoclax as the most potent cancer-specific drug for the CRCs from a CRPC patient. Other drug efficacies included taxanes, mepacrine, and retinoids.<h4>Conclusions</h4>Comprehensive cancer pharmacopeia-wide drug testing of CRCs from a CRPC patient highlighted both known and novel drug sensitivities in PCa, including navitoclax, which is currently being tested in clinical trials of CRPC.<h4>Patient summary</h4>We describe an approach to generate patient-derived cancer cells from advanced prostate cancer and apply such cells to discover drugs that could be applied in clinical trials for castration-resistant prostate cancer.Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.Saeed Khalid K, Rahkama Vesa V, Eldfors Samuli S, Bychkov Dmitry D, Mpindi John Patrick JP, Yadav Bhagwan B, Paavolainen Lassi L, Aittokallio Tero T, Heckman Caroline C, Wennerberg Krister K, Peehl Donna M DM, Horvath Peter P, Mirtti Tuomas T, Rannikko Antti A, Kallioniemi Olli O, Östling Päivi P, Af Hällström Taija M TMCRCS, Drugs, Drug, Products, Preparations, drugs, Pharmaceuticals., Patient, Product, Pharmaceutic Preparations, medicine, Pharmaceutical, Clients, Pharmaceutical Product, Pharmaceutic, patient, Preparation, Pharmaceutical Products, Medications, Client, Cell, Pharmaceutical PreparationUVO Gene Mutation, ERBB2 Gene Amplification Negative, Monomesylate, H. pylori Positive, CDH1 Wild-Type, Cytogenetically Normal, CEK Gene Mutation Negative, BCC7 Gene Mutation Negative, ESTRB Negative, ECT1 Gene Rearrangement Negative, Androgens Receptors, Tumor, ERBB2 Amplification, Positive Charge, dmTAF[[II]]230, TRT Promoter Mutation Negative, copy_number, GNA11 Gene Mutation Negative, Normal Tissue, RET/PTC Rearrangement, Hepatitis C Virus RNA Positive, p53 Mutation, SDTM-SETTING, Discover, PGR Positive, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification Negative, responsivity, Cultural, Accepted, node-negative, 1, 5, BRAF Wildtype, Analysis, 7, H. pylori Negative, study limitations, Hepatitis B Virus Core Antibody Negative, Testosterone Receptor, DmelCG8669, Methylated MGMT Promoter, amyloidosis, In-house, ERA Positive, No rearrangement detected, HER2/neu Gene Mutation Negative, G Protein Subunit Alpha q Gene Mutation, Analyses, IDH Gene Mutation, CD324 Gene Mutation, cel, ESR Negative, FGFBR Gene Mutation Negative, Hepatitis B Virus Core Antibody Positive, c-KIT Positive, KGFR Gene Mutation Negative, PDCD1L1 Negative, N, result, Flavoprotein Subunit of Complex II Positive, Tissue, F20O9.210, B7H1 Positive, BEK Gene Mutation, CRUCIFERIN C, MET Amplification Negative, node-positive, Cadherin 1 Gene Mutation, ESTRB Positive, HER2 Non-Amplified, XH2 Gene Mutation, Based, PGR Negative, ATRX Mutation Negative, XNP Gene Mutation Negative, Be, Cancer of the Prostate, Catenin Beta 1 Gene Mutation, ER Beta Positive, 4-Pentanediamine, FMS-Like Tyrosine Kinase 2 Gene Rearrangement Negative, PAX8 Gene Rearrangement Negative, Homo sapiens disease, Telomerase Reverse Transcriptase Gene Promoter Mutation, FGFR1 Rearrangement Negative, Atabrine, Methylated MGMT Gene Promoter, colorectal (colon or rectal) cancer, Forested Area, Tumors, Nervous system-specific RNA-binding protein Hel-N1, dTAF[[II]]230, Apply, TP53 Gene Mutation Negative, Human Immunodeficiency Virus Positive, Anti-HBc Negative, KGFR Gene Rearrangement, c-erbB2 Gene Amplification, potp, Serum CA 19-9 Normal, Learning from Labeled Data, assessment, TP53 Mutation Negative, arteria cerebri communicans posterior, B-RAF Gene Rearrangement, Anti-HBc Positive, BRAF wt, familial cutaneous lichen, Test, Normal skin, PARENT, Curative, Normalcy, Hepatitis B Virus Surface Antibody Positive, Estrogen Receptor Alpha Positive, Active Machine, copy number, 1p/19q Co-deletion Negative, Human Immunodeficiency Virus Negative, Androgen, TMEM16A Negative, Benign, Cultures, SDHIP Positive, (R)-Isomer, CTNNB1 Wildtype, Pca, SEND-DESIGN, FGFR-2 Gene Rearrangement, FLT2 Gene Mutation, FGFR-1 Gene Rearrangement, LCAM Gene Mutation Negative, Flavoprotein Subunit of Complex II Negative, RET Gene Rearrangement, Ret Proto-Oncogene Rearrangement Negative, FGFR3 Wild-Type, Lab Test, oligonucleotide random primer, Stanolone, NRAS Gene Mutation, Test Name, Cultural Beliefs, ECAD Gene Mutation, Dihydrotestosterone, HUB, Benign Neoplasms, Androgen Receptor Negative, EST2 Promoter Mutation, B7-H Negative, cancer of prostate, Present, ESR Positive, PDCD1L1 Positive, c-KIT Negative, Malignant Neoplasms, ATF-4, p16INK4a Negative, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement Negative, Positive EBV Serum Test, IDH Gene Family Mutation, Taf250, ATRX Gene Mutation Negative, Image Analysis, Unmethylated O-6-Methylguanine-DNA Methyltransferase Gene Promoter, Cells, EBV Negative, Whole Exome Sequencing, N-RAS Gene Mutation, HER2/Neu Amplification, cancer of the large bowel, Cell Cultures, TRP53 Gene Mutation Negative, Nepal Bhasa, KRAS Gene Mutation, B7H1 Negative, Expression of PD-L1, ATF4/crc, Hepatitis B Core Antibody Negative, CRCS, WHOLE EXOME SEQUENCING, SDHF Positive, Nuclear Receptor Subfamily 3 Group A Member 2 Positive, Clr, Quinacrine Monohydrochloride, BRCA1-Associated Protein 1 Gene Mutation, Neoplasms, CDHE Gene Mutation, HER-2 Gene Mutation Negative, B-RAF1 Gene Rearrangement Negative, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation Negative, Anti-HBc Antibody Negative, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Hepatitis B Virus Surface Antigen Positive, colorectal cancer, New Lesion, SDHF Negative, BRCA1 Associated Protein 1 Gene Mutation Negative, K-SAM Gene Mutation Negative, Nuclear Receptor Subfamily 3 Group A Member 2 Negative, N-SAM Gene Rearrangement Negative, NRAS Wildtype, Cancer of Prostate, G Protein Subunit Alpha 11 Gene Mutation, CD333 Gene Mutation Negative, Expression Negative, KRAS Wildtype, GNA11 Wild-Type, ETV Rearrangement Negative, Quinacrine Monomesylate, Passive Cutaneous, ESR1 Negative, B7-H Positive, c-MET Gene Amplification Negative, Cadherin-Associated Protein, B-RAF1 Gene Mutation Negative, dTAF[[II]]250, Clinical, MGMT Gene Methylation, Hepatitis B Core Antibody Positive, cell, Tissues, FGFR1 Gene Mutation Negative, FGFR-2 Gene Mutation Negative, CDH1 Mutation Negative, Cultural Relativisms, Transcriptomics, Image Processing, FGFR-2 Gene Rearrangement Negative, SDHA Negative, outcome, KRAS2 Gene Mutation Negative, BEK Gene Rearrangement, cancer of the large intestine, Neoplasias, RET Rearrangement, dTAF250, Alpha 11 Gene Mutation Negative, drugs, RAD54 Homolog Gene Mutation, synopsis, Estrogen Receptor Alpha Negative, ETV Family Rearrangement Negative, FLT2 Gene Mutation Negative, Keratinocyte Growth Factor Receptor Gene Rearrangement Negative, Prostatic, genome, ERBB2 wt, MFSD7B, p53 Gene Mutation Negative, HBsAg Negative, HER-2 Gene Amplification, Including, NORMAL, Pharmaceuticals, New, inhibitors, Positive EBV Test, Hepatitis B Virus Surface Antibody Negative, Q Polypeptide Gene Mutation Negative, Malignant Neoplasm, Fibroblast Growth Factor Receptor 1 Gene Rearrangement Negative, CURATIVE, ETS Transcription Factor ERG Gene Rearrangement Negative, Progenitor Cells, PR Positive, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, Hepatitis B Surface Protein Antigen Positive, disorders, SDHIP Negative, WXS, Estrogen Receptor Positive, eth, FGFR2 Wild-Type, Cultural Backgrounds, Negative Number, dTAF230, B-RAF1 Gene Rearrangement, Beta Catenin Gene Mutation Negative, del(10q23)/PTEN Gene Locus Deletion Negative, ATRX, CTNNB1 Gene Mutation Negative, MT, BRAF Gene Rearrangement, Prostatic Cancer, condition, TP53 wt, clinical, FLG Gene Mutation, PAX8 Rearrangement, Crc, Alpha-11 Gene Mutation Negative, Androgen Receptor Positive, Approach, HGFR Gene Amplification, ESR1 Positive, Hepatitis B Surface Protein Antigen Negative, NEGATIVE, lab exam, mRNA Differential Display, Quantify, MET Gene Amplification, c-MET Gene Amplification, Lab Tests, Mandatory, 5 alpha-Dihydrotestosterone Receptor, Paired Domain Gene 8 Gene Rearrangement Negative, ER-Alpha Positive, Taf[[II]]250, New Lesion Identification, Copy Number, Castrations, alpha-Dihydrotestosterone Receptor, BEK Gene Mutation Negative, Methylated MGMT, Unmethylated MGMT Promoter, mRNA, ERG Rearrangement, choanal atresia, SHARED, HBsAg Positive, crc, BCL2 Family Protein, Differential Displays, CRIB, malignant tumor, TERT Gene Promoter Mutation, Hu-antigen B, ERBB2 Wildtype, No, Blood Products, Generated, Ret Proto-Oncogene Rearrangement, Machine Learning with a Teacher, crt, colon cancer, Lack of Expression of PD-L1, Primary Cause of Death, Catenin Beta 1 Gene Mutation Negative, Specific, IDH Mutation, 1p/19q Co-deletion, SDHA Positive, PC, Q Polypeptide Gene Mutation, ttw, Relativism, Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Neoplasia, Estrogen Receptor 2 Positive, Anti-Hepatitis B Core Antibody Negative, author summary, XNP Gene Mutation, O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation, Derived, Quinacrine Dihydrochloride, Forestland, LFS1 Gene Mutation Negative, ER Positive, Normal Male External Genitalia, BAP1 Wildtype, Telomerase Reverse Transcriptase Gene Promoter Mutation Negative, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement, clinical data, Characterization, Nurture, Human Herpesvirus-4 Negative, CRPC., Supervised Machine, protein expression, Quinacrine Monoacetate, HRAS1 Gene Mutation, G-ALPHA-q Gene Mutation, Transcript Expression Analysis, DHTR, BAP1 Gene Mutation, Pharmaceutical Product, Mathematical Derivation, Gene Expression Monitorings, ESR2 Negative, Newari, hel-n1, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation, ORAOV2 Negative, Whole-Exome Sequencing, ABT-263, TP53, Abnormal, Gonadectomies, gene expression, ATRX Wildtype, BRAF Mutation Negative, DESIGN, human disease, ESR-Beta Negative, Estrogen Receptor Beta Positive, Retinoid, Identification, CD274 Negative, DOG1 Positive, Keratinocyte Growth Factor Receptor Gene Mutation Negative, twy, BAP1 wt, ETV Family Gene Rearrangement, Ets Variant Family Rearrangement, Stanolone Receptors, FLT2 Gene Rearrangement, PAX8 Rearrangement Negative, Rearrangement identified, BCL2 Family, Novel, How Often Felt Normal, FGFR3 Gene Rearrangement, Chromatin Remodeler Gene Mutation Negative, Cure, FGFR-1 Gene Rearrangement Negative, ECT1 Gene Mutation, Estrogen Receptor 1 Positive, Fibroblast Growth Factor Receptor 2 Gene Mutation, Erb-B2 Receptor Tyrosine Kinase Gene Mutation Negative, Pharmaceutical, IDH Family Mutation, Subsequent, CD333 Gene Rearrangement, Normal, None detected, Testosterone, BAP1 Wild-Type, ER-Alpha Negative, None Detected, ATRX Gene Mutation, SDHB Loss, ERG Gene Rearrangement, Ha-ras Gene Mutation Negative, cancer of the prostate, Primary Tumor, GNA-11 Gene Mutation Negative, GNAQ Wildtype, Monohydrochloride, HBsAb Negative, Biological Property, FGFR-1 Gene Mutation Negative, Negative, Castration-Resistant Prostate Carcinoma, HER2 Gene Mutation, TAFII-250, Semi supervised Learning, TAF250/230, results, FLT-2 Gene Mutation Negative, BRAF Wild Type, Gene Expression, Monoacetate, Ets Variant Gene Family Rearrangement Negative, TAFII250, C76301, ESRA Negative, FGFR3 Rearrangement Negative, Stem Cell, Hepatitis B Surface Antibody Positive, KAL2 Gene Mutation Negative, ESTRR Negative, Areas, HIV Positive, PRCDTH, Taxoid, Classical CRC, Fibroblast Growth Factor Receptor 2 Gene Mutation Negative, anon-EST:fe3D7, CRPC, HIV positive, 1p/19q Codeletion, FGFR2 Mutation Negative, POSITIVE, p16INK4 Negative, Guanine Nucleotide Binding Protein (G Protein), Parent, Yes, 5 alpha-Dihydrotestosterone, Derivation, resistant, Quantitation, HHV-4 Negative, Stem, Tests, SDH2 Positive, susceptibility to, HRAS Gene Mutation Negative, E-Cadherin Gene Mutation Negative, ERBB2 Gene Mutation, Colony Forming Units, estrogen receptor negative, CG17603, TAF[[II]], 1p/19q Intact, HER2 Wildtype, ABT 263, disease, FLT-2 Gene Rearrangement Negative, Expressed, ER-Beta Positive, Base, p45, Assess, Androgen Receptor, CG8669, HRAS Gene Mutation, Tumor Protein p53 Gene Mutation Negative, Expression Analysis, Unmethylated MGMT Gene Promoter, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Prostate, AI118201, PR Negative, BRAF Rearrangement, Normal Chest Appearance, Passive, CD203c, CDH1 Gene Mutation, NPP1, KAL2 Gene Rearrangement Negative, Prostate Neoplasms, tissue, Shared, GAQ Gene Mutation Negative, Negative Finding, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Negative, Progenitor Cell, Anti-HBs Positive, c-erbB2 Gene Activation, dTAFII250, Development, broad, Established, SETTING, elavl2, Malignant, JKT4 Gene Mutation Negative, FGFR1 Wildtype, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation Negative, Homo sapiens, OGD Gene Mutation Negative, Fp Positive, dmTAF1, Fibroblast Growth Factor Receptor 1 Gene Rearrangement, Seven, OGD Gene Mutation, SDHB Deficient, Anti-HBcAb Positive, Test Dosing Unit, Hep C RNA Positive, clone 2.11, Anti-Hepatitis B Virus Surface Antibody Negative, Cell Culture, Progenitor, c-K-ras Gene Mutation Negative, CD274 Antigen Positive, Epithelial Gene Mutation, primary, TAF250, MET Proto-Oncogene, Mitochondrial Negative, reactivity, NR3A1 Negative, HHV4 Negative, clone 2.17, NRAS Wild-Type, SWS Gene Mutation, TAOS2 Positive, GNA11 Wildtype, Being, biparietal Alzheimer disease, Scrb1, Normal Gait, G-ALPHA-q Gene Mutation Negative, Transcript Expression, Transcriptome Analysis, PDL1 Negative, Methylguanine-DNA Methyltransferase Gene Promoter Methylation, FGFR1 Gene Rearrangement Negative, CD331 Gene Mutation Negative, p16(INK4a) Negative, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation, H-ras Gene Mutation, ETV Gene Rearrangement, inhibidor, Inductive Machine, Erg-3 Gene Rearrangement Negative, Clients, vartul, CD332 Gene Rearrangement, Ets Variant Gene Family Rearrangement, Normal Abdomen on Visual Inspection, disorder, N-RAS Gene Mutation Negative, HER2 Gene Amplification, Preparation, TAF, Expression Analyses, CTNNB Gene Mutation, progesterone receptor positive, RASH1 Gene Mutation, KGFR Gene Rearrangement Negative, Profiling, CD332 Gene Rearrangement Negative, TAF[[II]]250, Succinate Dehydrogenase Complex Flavoprotein Subunit A Negative, Transcriptome, ABT263, FLG Gene Rearrangement Negative, Anti-Hepatitis B Virus Core Antibody Positive, Beta Gene Mutation Negative, SCRIB1, FGFR3 Gene Mutation Negative, l(3)84Ab, FGFR1 Mutation Negative, Technology, medical condition, Normal Precordial Palpation Finding, Anti-HBs Antibody Negative, DRVFL, NR3A2 Positive, ENABLE, AI428932, p230, Applied, MGMT Gene Promoter Methylation, GNA11 wt, BCL-2 Family, Conditionally Reprogrammed Cells, TMEM16A Positive, Catenin Beta-1 Gene Mutation, MGMT Methylation, AR Positive, Gonadectomy, Random selection by shearing, antagonists, large bowel cancer, Metastatic Castration-Resistant Prostate Carcinoma, Anoctamin-1 Negative, ER Beta Negative, TAF[[II]]230, FMS-Like Tyrosine Kinase 2 Gene Mutation, UVO Gene Mutation Negative, Acrichine, HIV Positivity, Mast/Stem Cell Growth Factor Receptor Kit Positive, ERBB2 Mutation Negative, Normality, FGFR3 wt, Dihydrate, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Negative, Required, FGFR-2 Gene Mutation, KIT Negative, patient, ERA Negative, OGD Gene Rearrangement Negative, Dialect, B-RAF Gene Mutation Negative, CTNNB1 wt, Calcium-Dependent Adhesion Protein, Transcriptome Analyses, Absent, introduction, Drug, SDH1 Negative, DmelCG9429, Preparations, NEU Gene Amplification Negative, DmelCG17603, GTPase Gene Mutation Negative, CD324 Gene Mutation Negative, B7 Homolog 1 Negative, (S)-Isomer, NR3C4, IDH wt Allele, HBs Antigen Positive, CD274 Molecule Positive, BAP1 Gene Mutation Negative, Advise Before Life Ends, mel-N1, GTPase Gene Mutation, TAF1, Anti-HBsAb Positive, Beta Gene Mutation, Product, CDKN2A-p16(INK4a) Negative, Cyclin-Dependent Kinase 4 Inhibitor A Negative, Design, Hepatitis B Surface Antigen Negative, Receptors, Progesterone Receptor Positive, FGFBR Gene Rearrangement, GNAQ Gene Mutation Negative, CDH1 Wildtype, UCHL2 Gene Mutation Negative, limitations, Nuclear Receptor Subfamily 3 Group A Member 1 Negative, GNAQ Mutation Negative, Progesterone Receptor Negative, FGFR-3 Gene Mutation Negative, H-ras Gene Mutation Negative, Normal Appearance of the Extremities, C-HA-RAS1 Gene Mutation Negative, Industrialization, Nuclear Receptor Subfamily 3 Group A Member 1 Positive, Generation, Industrial Developments, Profilings, CDKN2A-p16 Negative, Erg-3 Gene Rearrangement, CD332 Gene Mutation, Benson syndrome, Ha-ras Gene Mutation, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Negative, Atf4, 929, average, Project ENABLE, EXPRESSED, ethnicity, HRas Proto-Oncogene, Loss of Expression, BFGFR Gene Rearrangement Negative, Laboratory Test, 2D Classical Conditionally Reprogrammed Cells, TFIID TAF250, TRT Promoter Mutation, HBcAb Negative, GAQ Gene Mutation, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification, Isocitrate Dehydrogenase (NADP+) Gene Family Wildtype, Cytogenetic Abnormalities Absent, FGFR1 Gene Rearrangement, IP Negative, Normality-Based Dosing Unit, PD-L1+, Normal Capillary Refill Time, NEU Gene Mutation, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement, Gene Expression Analysis, N4-(6-chloro-2-methoxy-9-acridinyl)-N1, Anti-HBsAb Negative, Dihydrotestosterone Receptors, FGFR3 Gene Mutation, SDHB Positive, medicine, Statistically, K-RAS Mutation, Receptor Tyrosine Kinase Gene Amplification Negative, Familiar, Statistics, CD331 Gene Rearrangement, COPYNUM, Catenin Beta-1 Gene Mutation Negative, C-HA-RAS1 Gene Mutation, MET Amplification, ZNF-HX Gene Mutation, Negative Charge, HBs Antigen Negative, Taxanes, Comprehensive, ERBB2 Gene Amplification, Beta Catenin Gene Mutation, FGFR-3 Gene Rearrangement Negative, ER Alpha Negative, ERB Negative, ERBB2 Wild-Type, FGFR1 wt, Followed By, CDH1 Gene Mutation Negative, Pdnp1, Exome, familial, TAF200, Monitorings, Derived Flag, Alpha 11 Gene Mutation, GNA11 Mutation Negative, el-1, Cultural Background, 4833416E15Rik, CD331 Gene Mutation, Laboratory Procedure, ERB Positive, CD117 Negative, Cadherin, PCA, JKT4 Gene Rearrangement, Area, Helicobacter pylori Negative, Educate, HuB, TEST, l(2)crc, Arc-1 Gene Mutation Negative, CMC1 Gene Mutation, ELAV-like neuronal protein 1, BCL-2 Family Protein, Culture Technique, PCS, Atebrin, Industrial, HELN1, P53 Gene Mutation, Epstein Barr Virus Negative, EST2 Promoter Mutation Negative, HGFR Gene Amplification Negative, laboratory test, Guanine Nucleotide-Binding Protein, PAX8 Gene Rearrangement, Transcriptome Profilings, HRAS Mutation Negative, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Amplification Negative, NR3A1 Positive, Hub, Keratinocyte Growth Factor Receptor Gene Rearrangement, HER2 Amplification, elrB, Beta-Catenin Gene Mutation Negative, cancer of large bowel, ATRX wt, Developments, human, Genomic, Requisite, CD333 Gene Mutation, Characterized, Positive Epstein-Barr Virus Test, Phenotypes, Anti-Hepatitis B Virus Core Antibody Negative, HBs Negative, TERT Promoter Mutation Negative, ERG Gene Rearrangement Negative, Gene Expression Analyses, antagonists and inhibitors, primary tumor, GNAQ wt, CDHE Gene Mutation Negative, FGFBR Gene Mutation, CTNNB Gene Mutation Negative, TCS1 Promoter Mutation, MET Gene Amplification Negative, hub, KRAS Gene Mutation Negative, other neoplasm, BRAF Gene Mutation Negative, TAF230, BFGFR Gene Mutation, Epstein-Barr Virus Negative, c-Met Amplification Negative, Clinical Batch, HER2 Gene Mutation Negative, G Protein Subunit Alpha q Gene Mutation Negative, Not Expressed, HCV RNA Positive, Forested Areas, Negative Estrogen Receptor, HER2 wt, Technology Developments, ER+, Nervous system-specific RNA-binding protein Mel-N1, Human, Gene Expression Profilings, ER-, Receptor Tyrosine Kinase Gene Amplification, 5 alpha Dihydrotestosterone Receptor, FGFR1 Gene Mutation, mRNA Differential Displays, Gene Expression Pattern Analysis, p55 Gene Rearrangement, FLG Gene Rearrangement, CMC1 Gene Mutation Negative, Dimesylate, PDCD1LG1 Positive, FGFBR Gene Rearrangement Negative, Li-Fraumeni Syndrome Gene Mutation Negative, Requirement, disease or disorder, anon-EST:Liang-2.17, anon-EST:Liang-2.11, IDH Family Gene Mutation Negative, NRAS Gene Mutation Negative, Man, heln1, Application, Backgrounds, Negative Lymph Node, Normalities, ETV Rearrangement, androgen receptor positive, Normal Skin, HBs Positive, Technology Development, Positive Number, FGFR3 Mutation Negative, JKT4 Gene Rearrangement Negative, positive test result, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation, ZNF-HX Gene Mutation Negative, GA11 Gene Mutation Negative, Ets Variant Family Rearrangement Negative, Paired Box Gene 8 Gene Rearrangement Negative, Cured, GNAQ Gene Mutation, PDCD1LG1 Negative, Mepacrine, PD-L1 Positive, Monitoring, NEU Gene Mutation Negative, Cell Culture Technique, CTNNB1 Gene Mutation, FGFR2 Gene Rearrangement, del10q23/Phosphatase and Tensin Homolog Gene Locus Negative, ANO1 Positive, CTNNB1 Wild-Type, RAD54 Gene Mutation, Customs, lab_exam, NEG, ER-Beta Negative, Expression, BRCA1-Associated Protein 1 Gene Mutation Negative, Programmed Cell Death 1 Ligand 1 Negative, BFGFR Gene Mutation Negative, Cancer, TCS1 Promoter Mutation Negative, HER2/neu Gene Amplification Negative, hereditary prostate cancer, NEW, CD117 Positive, FGFR2 Gene Mutation, Products, Helicobacter pylori Positive, Epithelial Gene Mutation Negative, FGFR3 Wildtype, ESRB Positive, Result, Biological Properties, Primary, BG:DS00004.13, Classical Conditionally Reprogrammed Cells, CTNNB1 Mutation Negative, Hepatocyte Growth Factor Receptor Gene Amplification Negative, Cell, Differential Display, Positive Finding, M6S1, Exome Sequencing, TERT Gene Promoter Mutation Negative, Transcript Expression Analyses, Discovery, GNA11 Gene Mutation, Neoplasm, KRAS Wild-Type, TAF[[II]]250/230, Androgens, ATRX Wild-Type, CD333 Gene Rearrangement Negative, CRC, background, KIT Proto-Oncogene Tyrosine Protein Kinase Negative, Hepatocyte Growth Factor Receptor Gene Amplification, Environmental Setting, Androgen Receptors, ESRB Negative, B-RAF Gene Rearrangement Negative, (+-)-Isomer, RET Rearrangement Negative, Castration-Resistant Prostate Cancer, BRAF Rearrangement Negative, Gene Expression Monitoring, IDH Mutation Negative, Erb-B2 Receptor Tyrosine Kinase Gene Amplification Negative, primary cancer, Pharmaceutic Preparations, HBcAb Positive, p16 Negative, PD-L1 Negative, HER2 Gene Amplification Negative, Tumor Protein p53 Gene Mutation, Fibroblast Growth Factor Receptor 1 Gene Mutation Negative, Cancers, IP Positive, Hepatitis B Surface Antigen Positive, Normal Appearance of Extremities, Normal Capillary Refill, RAD54L Gene Mutation Negative, Derived Value, N-RAS Mutation, FLT-2 Gene Mutation, ETS Transcription Factor ERG Gene Rearrangement, LAB_SEQ_METHOD, Fibroblast Growth Factor Receptor 3 Gene Rearrangement Negative, Forestlands, Xel-1, N1-diethyl-, IDP Gene Mutation Negative, NRAS Mutation Negative, CDH1 wt, ETV Family Gene Rearrangement Negative, CEK Gene Mutation, ANO1 Negative, Relativisms, prostate cancer, FGFR1 Wild-Type, Receptor, p16-INK4 Negative, Alpha-11 Gene Mutation, Statistical, Cultural Relativism, Laboratory Testing, Pharmaceutical Products, Forest, Chromatin Remodeler Gene Mutation, CEK Gene Rearrangement Negative, Fibroblast Growth Factor Receptor 1 Gene Mutation, insensitive, Languages, cure, SWS Gene Mutation Negative, G Protein Subunit Alpha 11 Gene Mutation Negative, objective, Hepatitis C Viral RNA Positive, ER Negative, FLT-2 Gene Rearrangement, laboratory_test, JKT4 Gene Mutation, AR+, F20O9_210, KRAS Mutation, BRAF Gene Rearrangement Negative, Background, ESR-Beta Positive, Fibroblast Growth Factor Receptor 2 Gene Rearrangement, FGFR-3 Gene Rearrangement, diseases, FLG Gene Mutation Negative, Forested, Mother Cells, diseases and disorders, HRAS Wild-Type, KGFR Gene Mutation, Human Herpesvirus 4 Negative, BAP1 Mutation Negative, estrogen receptor positive, CD332 Gene Mutation Negative, Copy Number Reported, No mutation detected, Pca-1, Man (Taxonomy), Protein Expression, WXS (whole exome sequencing), p55 Gene Rearrangement Negative, Cyclin-Dependent Kinase Inhibitor 2A Negative, Woodland, CD331 Gene Rearrangement Negative, Quinacrine Dihyrochloride, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation, large intestine cancer, Prostatic Neoplasm, c-Met Gene Amplification, PR+, FMS-Like Tyrosine Kinase 2 Gene Rearrangement, PR-, malignant neoplasm, Dihydrochloride, TP53 Wildtype, Quinacrine Dimesylate, FGFR2 Gene Rearrangement Negative, Anti-Hepatitis B Core Antibody Positive, Estrogen Receptor 2 Negative, FGFR2 Gene Mutation Negative, B7 Homolog 1 Positive, DERIVED, Beta 1 (88kD) Gene Mutation, Inductive Machine Learning, Malignancies, Positive, Inductive, Outcome, CD274 Molecule Negative, somatic mutation, Active Machine Learning, SDH2 Negative, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, Normal Thoracic Appearance, negative test result, FMS-Like Tyrosine Kinase 2 Gene Mutation Negative, Estrogen Receptor 1 Negative, wide/broad, Anti-HBs Antibody Positive, XH2 Gene Mutation Negative, TP53 Gene Mutation, Modern, Learning, Paired Box 8 Gene Rearrangement Negative, Hepatitis B Surface Antibody Negative, Normal Reference Range, 1p/19q co-deletion, KIT Proto-Oncogene Tyrosine Protein Kinase Positive, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Semi-supervised, Positive Estrogen Receptor, NR3A2 Negative, HBsAb Positive, K-SAM Gene Mutation, Succinate Dehydrogenase Complex Flavoprotein Subunit A Positive, Colony-Forming Unit, HRAS wt, Primary Neoplasm, Diseases, Common, POSTERIOR, NOS, Pharmaceutic, Estrogen Receptor Negative, Assessed, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Positive, AXPC1, Study Design, KRAS2 Gene Mutation, Normal Immune Presence, ETV Gene Rearrangement Negative, Clinical Data, Mother Cell, BCL-2 Family Proteins, IDH Gene Family Wildtype, Quinacrine Hydrochloride, cruciferin 3, HER-2 Gene Amplification Negative, Paired Domain Gene 8 Gene Rearrangement, Dialects, ERBB2 Gene Mutation Negative, RASH1 Gene Mutation Negative, IDH Gene Mutation Negative, Isocitrate Dehydrogenase Gene Family Wild Type, GNAQ Wild-Type, 10q23/PTEN Locus Deletion Negative, Anaphylaxis, Exist, Programmed Cell Death 1 Ligand 1 Positive, ESR2 Positive, BEK Gene Rearrangement Negative, Hepatitis C RNA Positive, Type 1, summary, Identified, Positive Laboratory Test Result, Paired Box 8 Gene Rearrangement, ECAD Gene Mutation Negative, wide, LCAM Gene Mutation, Health, Patient, SR3-5, DOG1 Negative, E-Cadherin Gene Mutation, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative, FGFR2 Wildtype, PC-1, Hepatitis B Virus Surface Antigen Negative, cancer of large intestine, mKIAA0147, Arc-1 Gene Mutation, Ly-41, N-SAM Gene Mutation, N-SAM Gene Rearrangement, CDISC SEND Study Design Terminology, CD274 Positive, other disease, Quinacrine, Quantification, d230, human being, LOST, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation Negative, Material Identification, KRAS-2 Gene Mutation, Colony-Forming Units, PDL1 Positive, Benign Neoplasm, Semi-supervised Learning, IDH Family Wildtype, Gene, KIT Positive, Anti-HBc Antibody Positive, TERT Promoter Mutation, ECT1 Gene Mutation Negative, EfW1, KAL2 Gene Mutation, autosomal dominant, ECT1 Gene Rearrangement, Anti-HBcAb Negative, FGFR2 wt, Anoctamin-1 Positive, FGFR-3 Gene Mutation, dATF-4, Taf230, FLT2 Gene Rearrangement Negative, CD274 Antigen Negative, HRAS Wildtype, Prostatic Cancers, Anti-Hepatitis B Virus Surface Antibody Positive, Fp Negative, Negative Test Result, Anti-HBs Negative, Next, HIV test positive, Prostate Cancers, FGFR3 Gene Rearrangement Negative, N-SAM Gene Mutation Negative, Npps, Drugs, FLVCR, Erb-B2 Receptor Tyrosine Kinase Gene Mutation, BFGFR Gene Rearrangement, Taf200, WES, SDHB Deficiency, Woodlands, 1p/19q Codeletion Negative, Malignancy, Machine Learning, Fibroblast Growth Factor Receptor 3 Gene Mutation, Cadherin 1, Mast/Stem Cell Growth Factor Receptor Kit Negative, CG9429, E-Cadherin (Epithelial) Gene Mutation, HER2/neu Gene Mutation, inhibiteur, Mother, Taf1p, Ire1, BRCA1 Associated Protein 1 Gene Mutation, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive, lichen amyloidosis, RAD54 Gene Mutation Negative, non-neoplastic, In-House, Positive Lymph Node, RANDOM, TISSUE, Newar Language, Following, C-H-RAS Gene Mutation, OGD Gene Rearrangement, culture, KAL2 Gene Rearrangement, Known, SDH1 Positive, ER Alpha Positive, statistical analysis, Cadherin 1 Gene Mutation Negative, UCHL2 Gene Mutation, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation Negative, RAD54L Gene Mutation, AR Negative, GNA-11 Gene Mutation, Colony Forming Unit, Culture Techniques, RET Gene Rearrangement Negative, HIV Negative, CEK Gene Rearrangement, NRAS wt, KRAS-2 Gene Mutation Negative, del(1p/19q) Negative, HEL-N1, drug, Parental, inhibitor, FGFR2 Rearrangement Negative, ERBB2 Non-Amplified, Fibroblast Growth Factor Receptor 3 Gene Mutation Negative, Medications, Loss of Chromosomes 1p/19q, Client, ESTRR Positive, K-SAM Gene Rearrangement, Stanolone Receptor, KRAS wt, Cutaneous Anaphylaxis, Testing, TP2 Promoter Mutation Negative, IDH Wild Type, Blood Products Laboratory Testing, Clinical Lot, del(1p/19q), Normal Point of Maximum Impulse, HER2 Wild-Type, Fibroblast Growth Factor Receptor 3 Gene Rearrangement, Hydrochloride, Objective, TFIID, Active, Fibroblast Growth Factor Receptor 2 Gene Rearrangement Negative, ESRA Positive, ERG Rearrangement Negative, K-SAM Gene Rearrangement Negative, ERBB2 Mutation, Basic, progesterone receptor negative, ETV Family Rearrangement, Assessment, Beta-Catenin Gene Mutation, GA11 Gene Mutation, Transcriptome Profiling, xel-1, MGMT Gene Promoter Methylation Negative, CDISC SDTM Environmental Setting Terminology, Paired Box Gene 8 Gene Rearrangement, TP2 Promoter Mutation, Basis, ORAOV2 Positive, TAF[II]250, Unit of Concentration, RET/PTC Rearrangement Negative, Unmethylated Methylguanine-DNA Methyltransferase Gene Promoter, No abnormality detected, Prostate Neoplasm, Specified, BAP1 Mutation, c-K-ras Gene Mutation, Estrogen Receptor Beta Negative, PCARP, Supervised, Modern Man, DER, SDHB Negative, FGFR-1 Gene Mutation, Inclusive, E-NPP1, response, Clinical Trial Objective, Prostate Cancer, Mitochondrial Positive, Genome, Pharmaceutical Preparation, TAOS2 NegativeDrugs, hereditary prostate cancer, Products, Castrations, cancer of the prostate, insensitive, Product, resistant, Pharmaceutic Preparations, Prostate Neoplasms, Neoplasms, drug, familial, patient, Cancers, cancer of prostate, Client, Cell, Prostate Neoplasm, Prostate Cancers., Drug, Preparations, Prostatic Neoplasm, drugs, Cancer of the Prostate, Patient, medicine, Pharmaceutical, Clients, Pharmaceutical Product, Prostatic Cancer, Neoplasm, Prostatic Cancers, Prostatic, prostate cancer, PC, NOS, Pharmaceutic, Preparation, Pharmaceutical Products, Cancer of Prostate, Prostate Cancer, Prostate, Pharmaceutical Preparation, Gonadectomies, Pharmaceuticals, Gonadectomy, Cancerribonucleic acid, Acid, RNA, Ribonucleic, simple tissue., ribose nucleic acid, Non Polyadenylated RNA, ribonucleic acids, Tissue, Non-Polyadenylated, RNS, patient, Ribonucleic Acid, Client, Cell, Non-Polyadenylated RNA, Patient, yeast nucleic acid, Clients, Ribonukleinsaeure, Gene Products, pentosenucleic acids, Ribonucleic acids, Non Polyadenylated, RNA Gene ProductsfalsePatient-derived conditionally reprogrammed cells (CRCs) were established and characterized to assess their biological properties and to apply these to test the efficacies of drugs.RNA seq data was used for the characterization and profiling of the created patient-derived cells and in vivo tissue.2017-07-26 15:39:27EGAS00001001702960627160946EGAD00001001923EGAC00001000429